-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290

Benzinga·08/14/2026 15:25:08
語音播報
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.